Activity value 72china Supplier,Last transaction date:
2026-01-02
Overview
Export data
Partners
HS Codes
Products
Areas
Ports
Trade trend analysis
Mon
|
Year
Number of TransactionsQuantityWeight
Number of TransactionsQuantityWeight
The above chart presents the market trend analysis for sichuan tongrentai pharmaceutical co.ltd. from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 4 transactions, with a transaction quantity of 6000 and a transaction weight of 0.
YearTransactionsQuantityWeight
202517333000
2026460000
Bill of lading data
<
1/15
>
Trade date
2026/01/02
B/L No.
7711828
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
s kant healthcare ltd.
Product description
ARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TOOTHER DRUGARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TO
Expand
Trade date
2026/01/02
B/L No.
5050774
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
s kant healthcare ltd.
Product description
ARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TOOTHER DRUGARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TO
Expand
Trade date
2026/01/02
B/L No.
6013747
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
s kant healthcare ltd.
Product description
ARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TOOTHER DRUGARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TO
Expand
Trade date
2026/01/02
B/L No.
3152328
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
s kant healthcare ltd.
Product description
ARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TOOTHER DRUGARTEMISININ DRUGS MEANT FOR FURTHER PROCESSING CONVERSION TO
Expand
Trade date
2025/10/01
B/L No.
——
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
ipca laboratories international
Product description
ARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TOOTHER DRUGARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TO
Expand
Trade date
2025/05/31
B/L No.
2395635
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
s kant healthcare ltd.
Product description
ARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TOOTHER DRUGARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TO
Expand
Trade date
2025/05/26
B/L No.
2281480
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
ipca laboratories international
Product description
ARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TOOTHER DRUGARTEMISININ-DRUGS MEANT FOR FURTHER PROCESSING/CONVERSION TO
Expand
Trade date
2025/03/19
B/L No.
7275115
Suppliers
sichuan tongrentai pharmaceutical co.ltd.
Buyers
ipca laboratories international
sichuan tongrentai pharmaceutical co.ltd. is china Supplier,
and primarily engages in the import and export business of products such as artemisinin,fur,pro.
According to the 52wmb.com global trade database, as of 2026-01-02, the company has completed 92 international trades,
with its main trading regions covering india etc.
The core products include HS29419019,HS29096000,HS29420090 etc,
and its main trading partners are s kant healthcare ltd.,ipca laboratories international,calyx chemicals pharmaceuticals ltd..
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on sichuan tongrentai pharmaceutical co.ltd. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.